International Isotopes, Inc.
I-131 Sodium Iodide & Other Radiochemicals
International Isotopes Inc. (OTCQB: INIS) is proud to be the only FDA approved Sodium Iodide I-131 drug product manufactured in the United States.
Nuclear Medicine Calibration Standards
Calibration standards are used for a range of applications in nuclear pharmacy from testing of imaging machines to calibration of patient dose measurement devices.
Cobalt Sealed Source Products
Our cobalt products are used by a broad array of companies for radiation treatment of cancer and vascular deformities of the brain. Cobalt sources are also used for container security examinations at our sea ports and borders.
Calibration Sources & Radioactive Standards
We are the North American distributor for LEA sources for control and calibration of equipment in the fields of radiation protection and metrology.
International Isotopes, Inc. Announces Highest Ever First Quarter Report
Idaho Falls, Idaho, May 16, 2023. International Isotopes Inc. (OTCQB: INIS) (the “Company”) is pleased to announce its financial results for the three months ended March 31, 2023.
Revenue for the three months ended March 31, 2023 was $3,089,535 as compared to $2,807,441 for the same period in 2022, an overall increase of approximately 10%. This was the Company’s highest reported revenue in the first quarter.
International Isotopes, Inc. Appoints Shahe Bagerdjian as President
International Isotopes, Inc. is pleased to announce that Shahe Bagerdjian has been appointed as President of the Company, effective immediately. Mr. Bagerdjian comes to INIS from Global Medical Solutions (GMS), a leading manufacturer and provider of radiopharmaceuticals and diagnostic imaging products for applications in nuclear medicine. While at GMS for over 10 years, Mr. Bagerdjian was responsible for implementing the short- and long-term strategy for the business as well as the day to day operations required to carry out those strategies.
Steve Laflin, CEO of INIS commented, “We are very pleased to have someone of Mr. Bagerdjian’s caliber join our team. His success at GMS is indicative of his high degree of business and management expertise, and his global knowledge and reputation is certain to become a valuable asset at INIS.”
Mr. Bagerdjian said, “I feel privileged joining INIS, a company with a legacy of superior customer service and diverse group of nuclear-focused business segments, including Cobalt-60, RadQual, and Iodine-131 theragnostic. I look forward to working closely with Steve and the entire INIS team.”
2022 Year End Financial Results:
Highest Single Year Revenue & Gross Profit in Company History
IDAHO FALLS, IDAHO, April 6, 2023. International Isotopes Inc. (OTCQB: INIS) (the “Company”) announces its financial results for the fiscal year ended December 31, 2022.
The following is a summary of significant accomplishments of the Company in 2022:
- Achieved $11.2 million in total revenues in 2022, a 16% increase compared to 2021. 2022 total revenue was the largest single year in company history.
- Net income was approximately $300,000 in 2022 compared to a net loss of about $900,000 in 2021.
Increased sales in the Radiochemical segment by 41% in 2022 through increases in sales of our FDA approved generic sodium iodide I‐131 drug product. - Completed the sale of certain unused assets for $4.0 million in cash, resulting in a net gain of $1.8 million.
- Developed several new products for our Nuclear Medicine products segment and expanded our product line into Positron Emission Tomography (PET) imaging standards.